ALVEOGENE
AlveoGene is an innovative company focused on transforming rare respiratory disease outcomes using inhaled gene therapy.
ALVEOGENE
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2022-01-01
Address:
Oxford, Oxfordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.alveogene.com
Total Employee:
1+
Status:
Active
Technology used in webpage:
Euro U.S. Server Location Pound Sterling
Similar Organizations
GW Pharmaceuticals
GW Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics.
Gyroscope Therapeutics
Gyroscope Therapeutics is a clinical-stage gene therapy company focused on developing therapies and treating diseases of the eye.
KaNDy Therapeutics
KaNDy Therapeutics is a clinical-stage company focused on optimising the potential of NT-814.
Pathios Therapeutics
Pathios Therapeutics is a biotech company focused on the development of therapies for autoimmune diseases and cancer.
PIC Therapeutics
PIC Therapeutics is a biotechnology company focused on transforming the treatment of cancer.
Vivoryon Therapeutics
Vivoryon is a clinical stage company focused on bringing first-in-class therapies to patients suffering from age-related diseases.
Tacalyx
Tacalyx is a biotech company focused on the discovery and development of novel anti-TACA
Trino Therapeutics
Trino is a drug company focused on developing anti-inflammatory drug candidates derived from a Taiwanese fern.
Investors List
Oxford Science Enterprises
Oxford Science Enterprises investment in Seed Round - AlveoGene
Old College Capital
Old College Capital investment in Seed Round - AlveoGene
Harrington Discovery Institute at University Hospitals
Harrington Discovery Institute at University Hospitals investment in Seed Round - AlveoGene
Official Site Inspections
http://www.alveogene.com
- Host name: 99.0.153.160.host.secureserver.net
- IP address: 160.153.0.99
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "AlveoGene"
Home - alveogene
Transforming Rare Respiratory Disease Outcomes Using Inhaled Gene TherapySee details»
About Us - alveogene
AlveoGene is led by David Hipkiss, Executive Chair and supported by its 6 academic founders who are core members of the UK Respiratory Gene Therapy Consortium (GTC). David is a biopharmaceutical executive with over 25 years’ …See details»
OHC Therapeutics Accelerator Company, AlveoGene, Receives …
Dec 3, 2024 AlveoGene was founded in 2023 as the first company being advanced under the Oxford-Harrington Rare Disease Centre Therapeutics Accelerator, with co-investment from …See details»
AlveoGene - Crunchbase Company Profile & Funding
AlveoGene may be growing as it has recently launched with a focus on developing inhaled gene therapies, indicating an expansion in its operations. The company has successfully closed …See details»
AlveoGene Launches to Develop Unique Inhaled Gene Therapies …
Sep 14, 2023 AlveoGene is the culmination of a successful collaboration between leading researchers from top-ranked UK universities, via GTC, and we believe the company has the …See details»
AlveoGene - LinkedIn
AlveoGene is an innovative company focused on transforming rare respiratory disease outcomes using inhaled gene therapy. AlveoGene has been created by OSE, Harrington and OCC in …See details»
Alveogene - Oxford Science Enterprises
Alveogene is targeting the genetic causes of serious respiratory diseases by leveraging the company’s InGenuiTy platform to deliver inhaled gene therapy to the site of action in the lungs. …See details»
AlveoGene Company Profile 2024: Valuation, Funding & Investors
AlveoGene General Information Description. Developer of gene therapy designed for patients suffering from respiratory diseases. The company has developed a treatment method where …See details»
AlveoGene Launches to Develop Unique Inhaled Gene Therapies …
Sep 14, 2023 New gene therapy company created and funded by Oxford Science Enterprises, Harrington Discovery Institute and Old College Capital in partnership with six leading scientists …See details»
AlveoGene Launches to Develop Unique Inhaled Gene Therapies …
September 14, 2023. AlveoGene Launches to Develop Unique Inhaled Gene Therapies for Rare Respiratory Disorders. New gene therapy company created and funded by Oxford Science …See details»
AlveoGene | VentureRadar
AlveoGene is a technology platform that specializes in the development of next-generation lentiviral delivery systems for the treatment of respiratory diseases. Their proprietary …See details»
AlveoGene launches to develop inhaled gene therapies for rare ...
AlveoGene will be led by David Hipkiss as Executive Chair. David is a biopharmaceutical executive with over 25 years experience of building and leading innovative companies, …See details»
News - alveogene
Nov 15, 2024 Executive Chair, David Hipkiss, will be attending JPM 2025 week in San Francisco week beginning 13th January 2025. He will be meeting with investors and partners and also …See details»
AlveoGene: inhaled gene therapy spinout launches
AlveoGene was founded on research by six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC), established in 2001 by the three universities to …See details»
AlveoGene Launches to Develop Unique Inhaled Gene Therapies …
Sep 14, 2023 Alveogene. New gene therapy company created and funded by Oxford Science Enterprises, Harrington Discovery Institute and Old College Capital in partnership with six …See details»
Alveogene - EU-Startups
AlveoGene is an innovative company focused on transforming rare respiratory disease outcomes using inhaled gene therapy.AlveoGene has been created by OSE, Harrington and OCC in …See details»
AlveoGene’s Novel, Inhaled Gene Therapy AVG-002 Receives …
Oxford, UK – 3 rd December 2024 – AlveoGene (or ‘the Company’, www.alveogene.com), a company focused on transforming rare respiratory disease outcomes using inhaled gene …See details»
AlveoGene Receives Rare Pediatric Disease Designation (RPDD) …
Sep 14, 2023 Oxford, UK – 15th November 2024 – AlveoGene (or ‘the Company’, www.alveogene.com), a company focused on transforming rare respiratory disease outcomes …See details»
AlveoGene’s Novel, Inhaled Gene Therapy AVG-002 Receives …
Sep 14, 2023 Oxford, UK – 3 December 2024 – AlveoGene (or ‘the Company’, www.alveogene.com), a company focused on transforming rare respiratory disease outcomes …See details»
AlveoGene debuts to develop inhaled gene therapy technology
Sep 14, 2023 AlveoGene will initially focus its R&D efforts on alpha-1 antitrypsin (AAT) deficiency, a degenerative condition that is one of the most common genetic diseases and can …See details»